

Emre Bilgin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3477739/publications.pdf>

Version: 2024-02-01

95
papers

412
citations

1040018

9
h-index

794568

19
g-index

97
all docs

97
docs citations

97
times ranked

724
citing authors

#	ARTICLE	IF	CITATIONS
1	The clinical features and treatment of eosinophilic granulomatosis with polyangiitis (EGPA) in Turkey: one or two distinct diseases?. Internal and Emergency Medicine, 2022, 17, 743-751.	2.0	3
2	Anxiety levels before biologic initiation and changes with treatment in patients with psoriatic arthritis: HUR-BIO biologic registry results. Clinical Rheumatology, 2022, , 1.	2.2	1
3	Comparison of cardiovascular, cancer and herpes zoster risk of tofacitinib versus etanercept: single-centre observational study. Rheumatology, 2022, 61, e267-e269.	1.9	5
4	Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0
5	Differences and similarities of proliferative and non-proliferative forms of biopsy-proven lupus nephritis: Single centre, cross-disciplinary experience. Lupus, 2022, 31, 1147-1156.	1.6	3
6	The frequency of Achilles and plantar calcaneal spurs in gout patients. Turkish Journal of Medical Sciences, 2021, 51, 1841-1848.	0.9	2
7	Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience. Turkish Journal of Medical Sciences, 2021, 51, 297-308.	0.9	11
8	PILE: a candidate prognostic score in cancer patients treated with immunotherapy. Clinical and Translational Oncology, 2021, 23, 1630-1636.	2.4	14
9	Association of disease characteristics with the temporal sequence of skin and musculoskeletal disease onset in psoriatic arthritis. British Journal of Dermatology, 2021, 184, 1202-1203.	1.5	0
10	Successful treatment of penile Mondorâ€™s disease with infliximab in a patient with Behçetâ€™s disease. Rheumatology, 2021, 60, e400-e401.	1.9	0
11	POS0633â€¦DURATION OF STARTING bDMARDs ARE ALMOST 3 TIMES LONGER IN RA PATIENTS THAN PsA PATIENTS: HUR-BIO REAL LIFE RESULTS. Annals of the Rheumatic Diseases, 2021, 80, 554.2-555.	0.9	0
12	POS0931â€¦RETENTION RATE AND TREATMENT RESPONSE OF BIOLOGICAL AGENTS IN ADVANCED SPINAL ANKYLOSIS AND BAMBOO SPINE: THE REAL LIFE DATA FROM THE HUR-BIO REGISTRY. Annals of the Rheumatic Diseases, 2021, 80, 728.2-729.	0.9	0
13	POS1070â€¦ANXIETY IN PSORIATIC ARTHRITIS PATIENTS: RESULTS FROM THE HUR-BIO BIOLOGIC REGISTRY. Annals of the Rheumatic Diseases, 2021, 80, 814-814.	0.9	0
14	AB0200â€¦TRENDS IN THE CHOICE OF FIRST BIOLOGIC AND TARGETED SYNTHETIC DMARD IN RHEUMATOID ARTHRITIS PATIENTS: 20-YEARS JOURNEY OF HUR-BIO REAL-LIFE REGISTRY. Annals of the Rheumatic Diseases, 2021, 80, 1124.2-1124.	0.9	1
15	POS1378â€¦COMPARISON OF DEMOGRAPHIC AND CLINICAL FEATURES OF FAMILIAL MEDITERRANEAN FEVER PATIENTS AND PATIENTS WITH AXIAL SPONDYLOARTHRITIS ACCOMPANYING FAMILIAL MEDITERRANEAN FEVER. Annals of the Rheumatic Diseases, 2021, 80, 971.1-971.	0.9	1
16	AB0347â€¦RENAL BIOPSY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: IS IT ONLY LUPUS NEPHRITIS?. Annals of the Rheumatic Diseases, 2021, 80, 1198.2-1199.	0.9	0
17	POS0568â€¦OBESITY RATES AND BMI ARE SIMILAR IN AGE AND SEX MATCHED RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND SPONDYLOARTHRITIS PATIENTS. Annals of the Rheumatic Diseases, 2021, 80, 518.3-519.	0.9	0
18	POS0793â€¦PREDICTORS OF END STAGE RENAL DISEASE IN THE RENAL BIOPSY PROVEN LUPUS NEPHRITIS. Annals of the Rheumatic Diseases, 2021, 80, 648.3-649.	0.9	0

#	ARTICLE	IF	CITATIONS
19	POS1004â€¦BOTH SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS PATIENTS HAVE STRONG FAMILY HISTORIES. Annals of the Rheumatic Diseases, 2021, 80, 770.2-771.	0.9	0
20	AB0201â€¦CHANGES IN THE PRESCRIPTION PATTERNS OF THE SECOND-LINE BIOLOGIC AND TARGETED SYNTHETIC DMARD IN RHEUMATOID ARTHRITIS PATIENTS: 20-YEARS JOURNEY OF HUR-BIO REAL-LIFE REGISTRY. Annals of the Rheumatic Diseases, 2021, 80, 1124.3-1125.	0.9	0
21	AB0535â€¦PRESCRIPTION PATTERNS OF THE SECOND BIOLOGIC DMARD IN PSORIATIC ARTHRITIS THROUGH THE LAST DECADE: HURBIO-PsA REAL LIFE EXPERIENCE. Annals of the Rheumatic Diseases, 2021, 80, 1299.1-1299.	0.9	0
22	POS0251â€¦ARE CLINICAL FEATURES AND OUTCOMES OF ANCA (+) EGPA PATIENTS DIFFERENT FROM ANCA NEGATIVE ONES?. Annals of the Rheumatic Diseases, 2021, 80, 347.2-348.	0.9	0
23	POS0255â€¦IMPACT OF PLASMA EXCHANGE (PLEX) IN SEVERE ANCA-ASSOCIATED VASCULITIS (AAV): A REAL-LIFE DATA FROM A PROSPECTIVE COHORT. Annals of the Rheumatic Diseases, 2021, 80, 350.1-350.	0.9	0
24	OP0125â€¦TOFACITINIB IN RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: EFFICACY AND SAFETY ANALYSIS FROM TREASURE REAL-LIFE DATA. Annals of the Rheumatic Diseases, 2021, 80, 69.1-70.	0.9	1
25	Iliac artery aneurysm in Behçetâ€™s syndrome: collaborative management is essential. Rheumatology, 2021, 60, iii32-iii34.	1.9	1
26	In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?. Rheumatology International, 2021, 41, 1915-1924.	3.0	1
27	c-ANCA positivity in a patient with relapsing polychondritis: Co-incidence or not? A case and review of the literature. Ulusal Romatoloji Dergisi, 2021, 13, 88-90.	0.0	0
28	Proposal of a new nomenclature for the underlying pathogenetic mechanism of severe Coronavirus Disease-19: â€œInflammatory Thrombosis with Immune Endotheliitisâ€. Rheumatology International, 2021, 41, 679-680.	3.0	10
29	Mediastinal mass in a patient with rheumatoid arthritis: lymphoid cystic thymic hyperplasia. Rheumatology Advances in Practice, 2021, 5, rkab049.	0.7	1
30	Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic. Turkish Journal of Medical Sciences, 2021, 51, 1615-1623.	0.9	6
31	Spinal and cerebral hematoma in systemic lupus erythematosus and antiphospholipid syndrome: is drug interaction the culprit?. Drug Metabolism and Personalized Therapy, 2021, .	0.6	0
32	Disease characteristics of psoriatic arthritis patients may differ according to age at psoriasis onset: cross-sectional data from the Psoriatic Arthritis-International Database. Clinical and Experimental Rheumatology, 2021, 39, 532-536.	0.8	0
33	Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TREASURE prospective data. Clinical and Experimental Rheumatology, 2021, 39, 852-858.	0.8	1
34	Comment on: Microscopic polyangiitis: clinical characteristics and long-term outcomes of 378 patients from the French Vasculitis Study Group Registry by Nguyen et al. Clinical and Experimental Rheumatology, 2021, 39 Suppl 128, 8.	0.8	0
35	Comment on: Hypereosinophilic bronchiolitis in ANCA-associated vasculitis: where does it stand? by Sebastiani et al. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 196.	0.8	0
36	Comment on: Hypereosinophilic bronchiolitis in ANCA-associated vasculitis: where does it stand? by Sebastiani et al.. Clinical and Experimental Rheumatology, 2021, 39, 196-196.	0.8	1

#	ARTICLE	IF	CITATIONS
37	Can we predict transition from psoriasis to psoriatic arthritis?. Ulusal Romatoloji Dergisi, 2021, 13, 121-128.	0.0	0
38	The influence of obesity on biological agents treatment response in psoriatic arthritis: HUR-BIO real life results. Ulusal Romatoloji Dergisi, 2021, 13, 107-115.	0.0	0
39	Disease characteristics of psoriatic arthritis patients may differ according to age at psoriasis onset: cross-sectional data from the Psoriatic Arthritis-International Database. Clinical and Experimental Rheumatology, 2021, 39, 532-536.	0.8	8
40	Some concerns from Turkey. Annals of the Rheumatic Diseases, 2020, 79, e15-e15.	0.9	1
41	Histopathological subgrouping versus renal risk score for the prediction of end-stage renal disease in ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2020, 79, 675-676.	0.9	17
42	Geoeidemiology and clinical characteristics of neonatal lupus erythematosus: a systematic literature review of individual patientsâ€™ data. Turkish Journal of Medical Sciences, 2020, 44, 281-290.	0.9	9
43	Temporomandibular disorders in ankylosing spondylitis: a cross-sectional, monocentric study. Rheumatology International, 2020, 40, 933-940.	3.0	6
44	AB0628â€¦EMERGING AUTOANTIBODIES PANEL (MYOSITIS ASSOCIATED AND MYOSITIS SPECIFIC ANTIBODIES) IN INFLAMMATORY MYOPATHIES: THE FREQUENCIES OF AND RELATIONSHIP WITH CLINICAL FEATURES. Annals of the Rheumatic Diseases, 2020, 79, 1609.2-1610.	0.9	0
45	FRI0336â€¦CONCOMITANT USE OF BIOLOGIC DMARDS WITH CSDMARDS INCREASES DRUG RETENTION RATE AND IMPROVES TREATMENT RESPONSE IN THE PSORIATIC ARTHRITIS. HUR-BIO REAL LIFE RESULTS. Annals of the Rheumatic Diseases, 2020, 79, 761.2-761.	0.9	0
46	AB0745â€¦REAL-LIFE EXPERIENCE FOR SECUKINUMAB IN PSORIATIC ARTHRITIS FROM HURBio-PsA DATABASE. Annals of the Rheumatic Diseases, 2020, 79, 1669-1670.	0.9	1
47	AB0331â€¦EFFICACY, RETENTION RATE AND PREDICTORS OF TOFACITINIB EFFICACY AND RETENTION IN RHEUMATOID ARTHRITIS PATIENTS: HUR-BIO REAL-LIFE EXPERIENCE. Annals of the Rheumatic Diseases, 2020, 79, 1464.2-1464.	0.9	0
48	AB0742â€¦CONVENTIONAL SYNTHETIC DMARDS IN PSORIATIC ARTHRITIS - CHANGING PRACTICE IN BIOLOGIC ERA: REAL-LIFE RESULTS FROM HURBIO-PsA REGISTRY. Annals of the Rheumatic Diseases, 2020, 79, 1667.1-1667.	0.9	0
49	AB1016â€¦RATE OF PREDEFINING DISEASE ACTIVITY, REMISSION AND RELAPSE OF ADULT-ONSET STILLâ€™S DISEASE: SYSTEMATIC LITERATURE REVIEW. Annals of the Rheumatic Diseases, 2020, 79, 1801.2-1801.	0.9	0
50	FRI0117â€¦INCIDENCE RATE OF HERPES ZOSTER IN RHEUMATOID ARTHRITIS PATIENTS UNDER TOFACITINIB: REAL-LIFE DATA FROM TURKEY â€™ HURBIO REGISTRY. Annals of the Rheumatic Diseases, 2020, 79, 640.3-640.	0.9	0
51	THU0380â€¦SECUKINUMAB IS FREQUENTLY PREFERRED IN MULTI ANTI-TNF RESISTANCE SPONDYLOARTHRITIS PATIENTS: HUR-BIO REAL LIFE RESULTS. Annals of the Rheumatic Diseases, 2020, 79, 423.2-424.	0.9	0
52	AB0763â€¦THE INFLUENCE OF OBESITY ON BIOLOGICAL DMARD TREATMENT RESPONSE IN PSORIATIC ARTHRITIS: HUR-BIO REAL LIFE RESULTS. Annals of the Rheumatic Diseases, 2020, 79, 1679-1680.	0.9	0
53	SAT0367â€¦EXTRA-ARTICULAR MANIFESTATIONS IN EARLY AXIAL SPONDYLOARTHRITIS: WHAT IS THEIR FREQUENCY? A SYSTEMATIC LITERATURE REVIEW INCLUDING 2854 PATIENTS. Annals of the Rheumatic Diseases, 2020, 79, 1130.1-1131.	0.9	1
54	SAT0443â€¦CONCOMITANT PSORIATIC ARTHRITIS AND INFLAMMATORY BOWEL DISEASE IN THE PSA BIOLOGICAL REGISTRY: HUR-BIO REAL LIFE RESULTS. Annals of the Rheumatic Diseases, 2020, 79, 1178-1179.	0.9	0

#	ARTICLE	IF	CITATIONS
55	AB0195â€¦FACTORS RELATED TO RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RHEUMATOID ARTHRITIS-RELATED INTERSTITIAL LUNG DISEASE. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1398.2-1398.	0.9	0
56	Treatment modalities in psoriatic arthritis. <i>Ulusal Romatoloji Dergisi</i> , 2020, 12, 46-53.	0.0	0
57	Clinical Characteristics and Outcome of ANCA-Associated Vasculitis; Experience of A Single Reference Vasculitis Center. <i>Acta Medica</i> , 2020, 51, 22-32.	0.2	0
58	Predictors of drug retention and treatment response in axial spondyloarthritis patients treated with certolizumab: real-life results from the HURBIO registry. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 609-614.	0.8	0
59	Proposal for a simple algorithm to differentiate adult-onset Stillâ€™s disease with other fever of unknown origin causes: a longitudinal prospective study. <i>Clinical Rheumatology</i> , 2019, 38, 1699-1706.	2.2	18
60	Influenza epidemiology and influenza vaccine effectiveness during the 2016â€“2017 season in the Global Influenza Hospital Surveillance Network (GIHSN). <i>BMC Public Health</i> , 2019, 19, 487.	2.9	33
61	Cancer incidence in familial Mediterranean fever patients: a retrospective analysis from central Anatolia. <i>Rheumatology International</i> , 2019, 39, 1045-1051.	3.0	4
62	Comment on: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. <i>Rheumatology</i> , 2019, 58, 925-925.	1.9	0
63	THU0565â€¦COMPARISON OF SURVIVAL RATES AMONG SUBGROUPS OF PATIENTS EVALUATED FOR FEVER OF UNKNOWN ORIGIN. , 2019, , .		0
64	SAT0214â€¦CLINICAL FEATURES OF ANEURYSMAL BEHÇET DISEASE. , 2019, , .		0
65	FRI0595â€¦MAY CANCER RISK BE DECREASED IN A LARGE COHORT OF CHILD AND ADULT FAMILIAL MEDITERRANEAN FEVER PATIENTS?. , 2019, , .		0
66	OP0168â€¦DERIVATION AND VALIDATION OF A NEW STILL ACTIVITY SCORE (SAS). , 2019, , .		0
67	THU0287â€¦ANEURYSM IN BEHÇETâ€™S DISEASE: MANAGEMENT, PROGNOSIS AND MORTALITY. , 2019, , .		0
68	THU0387â€¦ENTEROPATHIC ARTHRITIS PATIENTS UNDER BDMARD TREATMENTS HAD FREQUENTLY RADIOGRAPHIC SACROILIITIS: HUR-BIO REAL LIFE RESULTS. , 2019, , .		0
69	Comparison of Diagnostic Subgroup Survivals of Patients Who Admitted for Fever of Unknown Etiology Evaluation: Long-term Results of Single-centre, Prospective Study. <i>Flora: the Journal of Infectious Diseases and Clinical Microbiology = Infeksiyon HastalıklarÄ± Ve Klinik Mikrobiyoloji Dergisi</i> , 2019, 24, 199-206.	0.1	0
70	Familial Mediterranean Fever: New Insights Into Cancer Immunoprevention? Comment on the Article by Brenner et al. <i>Arthritis and Rheumatology</i> , 2018, 70, 1167-1167.	5.6	1
71	Increased psoriasis frequency in patients with familial Mediterranean fever. <i>Upsala Journal of Medical Sciences</i> , 2018, 123, 57-61.	0.9	11
72	The association of various social capital indicators and physical activity participation among Turkish adolescents. <i>Journal of Sport and Health Science</i> , 2018, 7, 27-33.	6.5	11

#	ARTICLE	IF	CITATIONS
73	Aspergillus Pneumonia in a Patient With Adult-Onset Still Disease Successfully Treated With Anakinra. <i>Journal of Clinical Rheumatology</i> , 2018, 24, 156-158.	0.9	4
74	Remission of relapsing polychondritis after successful treatment of myelodysplastic syndrome with azacitidine: a case and review of the literature. <i>Drug Metabolism and Personalized Therapy</i> , 2018, 33, 105-108.	0.6	9
75	Poor outcomes among elderly patients hospitalized for influenza-like illness. <i>Current Medical Research and Opinion</i> , 2018, 34, 1201-1207.	1.9	9
76	Blood group $\alpha^{\sim}A^{\sim}TM$ may have a possible modifier effect on familial Mediterranean fever and blood group $\alpha^{\sim}O^{\sim}TM$ may be associated with colchicine resistance. <i>Biomarkers in Medicine</i> , 2018, 12, 565-572.	1.4	5
77	SAT0594â€œ...Which one is more valuable for diagnosis of adult onset stillâ€™s disease? solely neutrophilia or leukocytosis with neutrophilia?. , 2018, , .		0
78	SAT0608â€œ...How to differentiate adult onset stillâ€™s disease from overall other causes of fever of unknown origin: results of a prospective study from a tertiary referral centre. , 2018, , .		0
79	AB1140â€œ...Comparison of cut-off values for ferritin to discriminate adult onset stillâ€™s disease from other causes of fever of unknown origin: results of a prospective study. , 2018, , .		0
80	Frequency of Respiratory Syncytial Virus Infection Among Patients Hospitalized for Influenza-like Diseases and its Impact on Mortality: Prospective, Multi-center Real Life Results. <i>Flora: the Journal of Infectious Diseases and Clinical Microbiology = Infeksiyon HastalÄ±klarÄ± Ve Klinik Mikrobiyoloji Dergisi</i> , 2018, 23, 172-178.	0.1	1
81	Comparing polyarteritis nodosa in children and adults: a single center study. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1016-1022.	1.9	30
82	AB0706â€œ...Ankylosing spondylitis patients with uveitis had better adalimumab retention rate: hur-bio real life results. , 2017, , .		1
83	Increased cancer risk in patients with periodontitis. <i>Current Medical Research and Opinion</i> , 2017, 33, 2195-2200.	1.9	38
84	AB0471â€œ...Wide heterogeneity in treatment protocols and inappropriate use of prednisolone for anti-ro/la associated-congenital heart block: a systematic review of 492 cases. , 2017, , .		0
85	FRI0342â€œ...Distribution of vasculitides in eastern mediterranean: results of a prospective cohort. , 2017, , .		0
86	THU0548â€œ...Psoriasis in patients with familial mediterranean fever. , 2017, , .		0
87	SAT0567â€œ...Demographic, Clinic and Laboratory Features of 755 Patients with Neonatal Lupus Erythematosus: Systematic Review. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 874.2-874.	0.9	0
88	AB0562â€œ...Demographic Characteristics and Distribution of The Vasculitides Frequencies: A Real- Life Experience of Vasculitis Center from Eastern Mediterranean. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1096.4-1097.	0.9	0
89	AB0641â€œ...Comparing the Characteristics of Adult and Pediatric Patients with Polyarteritis Nodosa. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1113.2-1114.	0.9	0
90	BehÃ§et Disease With Vascular Involvement. <i>Medicine (United States)</i> , 2015, 94, e494.	1.0	114

#	ARTICLE	IF	CITATIONS
91	Journey of Vasculitis at Hacettepe University: from the Establishment of University to the Hacettepe AAV Workshop, 2020. Acta Medica, 0, 52, 4-6.	0.2	1
92	Relationships Between Physical Activity Level, Health-Related Fitness, Academic Achievement, and Academic Self-Concept. Eğitim Ve Bilim, 0, , .	0.3	3
93	Neonatal Lupus Eritematozusa Bağlı Hematolojik, Hepatik, Nörolojik Ve Akciğer Tutulumunun Gelişimden Geçirilmesi: Hasta Bazlı Sistemik Literatür Taraması. Ankara Eğitim Ve Araştırma Hastanesi Tıp Dergisi, 0, , .	0.2	0
94	Conventional Synthetic Dmards in Psoriatic Arthritis: Changing Practice in Biologic Era; Real-Life Results from HURBIO-PsA Registry. Acta Medica, 0, , 1-7.	0.2	0
95	Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: Treasure real-life data. Clinical and Experimental Rheumatology, 0, , .	0.8	6